SFI
ITRM

Susquehanna Fundamental Investments’s Iterum Therapeutics ITRM Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,415
Closed -$37K – 1604
2021
Q3 		$37K Hold
4,415
– – ﹤0.01% 1665
2021
Q2 		$153K Buy
+4,415
New +$95.7K ﹤0.01% 1527

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.1% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Susquehanna Fundamental Investments's ITRM Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Iterum Therapeutics (ITRM) in Q4 2021, closing a stake of 4,415 shares — an estimated $37K sold.

Susquehanna Fundamental Investments first reported a position in ITRM in Q2 2021 and held it in 2 quarters. The position peaked at $153K in Q2 2021. 44 funds tracked by Wall St. Rank hold ITRM as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining Iterum Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 4,415 Iterum Therapeutics shares in Q4 2021, an estimated $37K.
  • Susquehanna Fundamental Investments first reported a position in Iterum Therapeutics in Q2 2021 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Iterum Therapeutics position peaked at $153K in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.